Peter has considerable experience in the discovery and development of cell and gene therapies from his time at GSK. He managed the analytical workstreams of lentiviral and CAR-T assets to support FIH studies. He has particular expertise in the development, qualification and tech transfer of PCR-based analytical methods, working with both internal and external (CDMO) partners to support clinical studies. He was part of an expert Working Group that authored vector copy number assay guidance for the British Pharmacopoeia.

At Complement, Peter has established and managed the company’s research laboratory, overseen implementation of a suite of analytical assays to support internal and external CMC activities, and supported the IND filing of CTx001 by managing authoring and review of the Module 3 sections.